Hospital
Kearney Regional Medical Center LLC
Kearney Regional Medical Center LLC was paid $1.76M by Medicaid between Jan 2018 and Dec 2021, across 108 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoKEARNEY REGIONAL MEDICAL CENTER LLC
KEARNEY, NE 68845
KEARNEY, NE 68845
33aNPI1265877567assigned 05/01/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.76M
24GClaims72,451
24DCodes billed108
24AFirst – last monthJan 2018 – Dec 2021
Compared with peers
Next to other General Acute Care Hospital providers in Nebraska
Rank by total paid#4 of 8
Median peer was paid$1.62M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,868 | $165K | |
| 2019 | 13,652 | $250K | |
| 2020 | 16,411 | $419K | |
| 2021 | 32,520 | $927K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 2,369 | 2,190 | $342K |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 491 | 419 | $265K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 13% | 2,275 | 2,084 | $225K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 6.6% | 346 | 331 | $117K |
| G0378 | Hospital observation service, per hour | 6.0% | 761 | 648 | $105K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.4% | 795 | 702 | $95K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.0% | 193 | 191 | $52K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 529 | 508 | $45K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 6,875 | 4,866 | $44K |
| 80053 | Comprehensive metabolic panel | 2.1% | 6,305 | 5,207 | $37K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 113 | 107 | $37K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 631 | 583 | $32K |
96 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 1,590 | $30K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 6,421 | $28K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 2,251 | $27K |
| 87631 | 1.3% | 164 | $22K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 60 | $22K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 90 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 1,223 | $20K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,134 | $15K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 19 | $15K |
| 71045 | Radiologic examination, chest; single view | <1% | 854 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 240 | $9K |
| 80061 | Lipid panel | <1% | 1,301 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 927 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,038 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 411 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 326 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 52 | $6K |
| 86140 | <1% | 1,538 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $5K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 363 | $5K |
| 85027 | <1% | 1,281 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 31 | $5K |
| 83880 | <1% | 424 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 871 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 196 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 436 | $4K |
| 93296 | <1% | 259 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 189 | $3K |
| 0099U | <1% | 14 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 602 | $3K |
| 84439 | <1% | 304 | $3K | |
| 83735 | <1% | 1,244 | $3K | |
| 73630 | <1% | 43 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 73 | $2K |
| 81003 | <1% | 978 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 79 | $2K |
| 87430 | <1% | 87 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 49 | $2K |
| 85610 | <1% | 1,267 | $2K | |
| 81025 | <1% | 534 | $2K | |
| 81001 | <1% | 960 | $2K | |
| 85007 | <1% | 741 | $2K | |
| 82607 | <1% | 163 | $2K | |
| 84484 | <1% | 875 | $1K | |
| 85652 | <1% | 517 | $1K | |
| 82550 | <1% | 1,009 | $1K | |
| 83690 | <1% | 406 | $1K | |
| 99285 | Emergency room visit (most serious) | <1% | 25 | $968.31 |
| 74019 | <1% | 14 | $932.44 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 45 | $694.26 |
| 84100 | <1% | 681 | $639.87 | |
| 85730 | <1% | 592 | $615.41 | |
| 97161 | <1% | 55 | $610.76 | |
| G0008 | Administration of influenza virus vaccine | <1% | 243 | $586.83 |
| 81015 | <1% | 357 | $582.70 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 454 | $546.00 |
| A9270 | Non-covered item or service | <1% | 979 | $514.98 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 483 | $511.45 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 498 | $441.63 |
| 83540 | <1% | 102 | $413.48 | |
| 73560 | <1% | 12 | $413.24 | |
| 82948 | <1% | 577 | $410.28 | |
| 83874 | <1% | 678 | $404.54 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 51 | $379.98 |
| 90686 | <1% | 121 | $371.09 | |
| 82553 | <1% | 714 | $365.73 | |
| 87420 | <1% | 31 | $346.34 | |
| 88342 | <1% | 30 | $316.92 | |
| 87186 | <1% | 53 | $239.02 | |
| 87081 | <1% | 32 | $233.10 | |
| 82150 | <1% | 244 | $232.76 | |
| 87077 | <1% | 84 | $224.96 | |
| 84145 | <1% | 134 | $216.56 | |
| 87807 | <1% | 14 | $207.20 | |
| 93299 | <1% | 12 | $170.31 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 12 | $144.39 |
| 82728 | <1% | 24 | $142.35 | |
| J2704 | Injection, propofol, 10 mg | <1% | 344 | $113.46 |
| 85379 | <1% | 134 | $103.43 | |
| 84466 | <1% | 13 | $93.56 | |
| 80306 | <1% | 55 | $82.24 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 277 | $72.15 |
| 90662 | <1% | 64 | $47.32 | |
| 84703 | <1% | 12 | $29.89 | |
| 87040 | <1% | 85 | $23.19 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 162 | $21.33 |
| 83550 | <1% | 40 | $9.61 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 870 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 234 | $0.00 |
| 96376 | 0% | 64 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 167 | $0.00 |
| 94760 | 0% | 75 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 33 | $0.00 |
| 83605 | 0% | 108 | $0.00 | |
| 90688 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCALHOUN, WILLIAM (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| South Shore Cardiology PC | South Weymouth, MA | $230K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.